Literature DB >> 34567939

Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy.

Takehiro Sejima1, Toshihiko Masago1, Manabu Yoshida2, Takeshi Nishi3, Yasunari Kawabata3, Yoshitsugu Tajima3, Tetsuya Yumioka4, Masashi Honda4, Atsushi Takenaka4.   

Abstract

Although immuno-oncology combination therapy with nivolumab plus ipilimumab has recently shown a notable antitumor effect for first-line metastatic renal cell carcinoma, the eradication of the disease is extremely rare. Moreover, conventional treatments for renal cell carcinoma show little efficacy in the case of a poor prognostic pathological feature of sarcomatoid dedifferentiation. We report a case of pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component after laparoscopic radical nephrectomy by nivolumab plus ipilimumab combination therapy. A 57-year-old male patient received four cycles of nivolumab plus ipilimumab and thirty cycles of nivolumab for local recurrence and liver metastasis after laparoscopic radical nephrectomy for T3a renal cell carcinoma with sarcomatoid component. He underwent partial hepatectomy for the remaining small hepatic lesion after immuno-oncology therapy. Pathology of the surgical specimen showed no viable cancer cells. The patient was alive with no evidence of disease a year after partial hepatectomy. Our case encourages clinicians to achieve a second cure for patients with recurrent metastatic renal cell carcinoma after radical nephrectomy even though the resected kidney pathology showed sarcomatoid component. © The Japan Society of Clinical Oncology 2021.

Entities:  

Keywords:  Complete response; Ipilimumab; Nephrectomy; Nivolumab; Renal cell carcinoma; Sarcomatoid component

Year:  2021        PMID: 34567939      PMCID: PMC8421495          DOI: 10.1007/s13691-021-00501-2

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  14 in total

Review 1.  Sarcomatoid renal carcinoma: the final common dedifferentiation pathway of renal epithelial malignancies.

Authors:  B Delahunt
Journal:  Pathology       Date:  1999-08       Impact factor: 5.306

2.  Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Authors:  Fumi Kawakami; Kanishka Sircar; Jaime Rodriguez-Canales; Bryan M Fellman; Diana L Urbauer; Pheroze Tamboli; Nizar M Tannir; Eric Jonasch; Ignacio I Wistuba; Christopher G Wood; Jose A Karam
Journal:  Cancer       Date:  2017-08-22       Impact factor: 6.860

3.  Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients.

Authors:  Michail Alevizakos; Apostolos Gaitanidis; Dimitrios Nasioudis; Pavlos Msaouel; Leonard J Appleman
Journal:  Clin Genitourin Cancer       Date:  2019-01-17       Impact factor: 2.872

4.  JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.

Authors:  Sounak Gupta; John C Cheville; Achim A Jungbluth; Yanming Zhang; Lei Zhang; Ying-Bei Chen; Satish K Tickoo; Samson W Fine; Anuradha Gopalan; Hikmat A Al-Ahmadie; Sahussapont J Sirintrapun; Kyle A Blum; Christine M Lohse; A Ari Hakimi; R Houston Thompson; Bradley C Leibovich; Michael F Berger; Maria E Arcila; Dara S Ross; Marc Ladanyi; Cristina R Antonescu; Victor E Reuter
Journal:  Mod Pathol       Date:  2019-04-17       Impact factor: 7.842

5.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Authors:  Nizar M Tannir; Sabina Signoretti; Toni K Choueiri; David F McDermott; Robert J Motzer; Abdallah Flaifel; Jean-Christophe Pignon; Miriam Ficial; Osvaldo Arén Frontera; Saby George; Thomas Powles; Frede Donskov; Michael R Harrison; Philippe Barthélémy; Scott S Tykodi; Judit Kocsis; Alain Ravaud; Jeronimo R Rodriguez-Cid; Sumanta K Pal; Andre M Murad; Yuko Ishii; Shruti Shally Saggi; M Brent McHenry; Brian I Rini
Journal:  Clin Cancer Res       Date:  2020-09-01       Impact factor: 12.531

Review 9.  Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

Authors:  Kristian M Hargadon; Coleman E Johnson; Corey J Williams
Journal:  Int Immunopharmacol       Date:  2018-07-02       Impact factor: 4.932

View more
  1 in total

Review 1.  The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.

Authors:  Hana Studentova; Nikol Rusarova; Andrea Ondruskova; Anezka Zemankova; Vladimir Student; Daniela Skanderova; Bohuslav Melichar
Journal:  Curr Oncol       Date:  2022-08-03       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.